Return on Equity: The amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Calculated as: Income from Continuing Operations / Total Common Equity
KalVista Pharmaceuticals, Inc. (KALV) had Return on Equity of -192.31% for the most recently reported fiscal year, ending 2025-04-30.
| Income Statement Financials | |
-- |
|
$-183.44M |
|
-- |
|
-- |
|
$188.00M |
|
$-188.00M |
|
$7.94M |
|
$-180.05M |
|
$-180.05M |
|
$-183.44M |
|
$-183.44M |
|
$-183.44M |
|
$-183.44M |
|
$-188.00M |
|
$-187.04M |
|
49.65M |
|
49.65M |
|
$-3.69 |
|
$-3.69 |
|
| Balance Sheet Financials | |
$241.69M |
|
$1.99M |
|
$9.08M |
|
$250.77M |
|
$45.17M |
|
-- |
|
$110.21M |
|
$155.38M |
|
$95.39M |
|
$95.39M |
|
$95.39M |
|
49.76M |
|
| Cash Flow Statement Financials | |
$-152.91M |
|
$91.02M |
|
$159.73M |
|
$31.79M |
|
$132.27M |
|
$100.48M |
|
$12.29M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
5.35 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-153.84M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
|
Return on Equity |
-192.31% |
-192.31% |
|
-73.15% |
|
-192.31% |
|
$1.92 |
|
$-3.10 |
|
$-3.08 |
|